Corporate | 7 May 2019 16:30

Biotest AG: Annual general meeting approves payout of dividend

DGAP-News: Biotest AG / Key word(s): AGM/EGM/AGM/EGM

07.05.2019 / 16:30
The issuer is solely responsible for the content of this announcement.

PRESS RELEASE

Biotest AG: Annual general meeting approves payout of dividend

– Dividend payout of EUR 0.04 per preference share

Dreieich/ Frankfurt a. M., 07 May 2019. At the annual general meeting (AGM) held on 07 May 2019 in Frankfurt/ Main, shareholders of Biotest AG approved the payment of a dividend. With 97.53 percent of the ordinary share capital represented at the meeting, a payment of EUR 0.04 per preference share was resolved with a high degree of approval. The overall dividend payment will amount to EUR 0.8 million.

The annual general meeting, with 130 shareholders and guests present, formally discharged the members of the Management Board and Supervisory Board for financial year 2018.

The full text of the speech given by the CEO of Biotest AG, Dr. Michael Ramroth, at the AGM is available at: https://www.biotest.com/de/en/investor_relations/shareholders_meeting_2019.cfm

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition, Biotest develops monoclonal antibodies in certain cancer indications and in systemic lupus erythematodes, an autoimmune disease, which are produced by recombinant technologies. Biotest has more than 1,700 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

IR contact
Dr Monika Buttkereit
Phone: +49-6103-801-4406
Mail: investor_relations@biotest.de

PR contact
Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
Preference shares: securities’ ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

07.05.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Biotest AG
	Landsteinerstraße 5
	63303 Dreieich
	Germany
Phone:	0 61 03 – 8 01-0
Fax:	0 61 03 – 8 01-150
E-mail:	investor_relations@biotest.de
Internet:	http://www.biotest.de
ISIN:	DE0005227235, DE0005227201
WKN:	522723, 522720
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	808139

End of News DGAP News Service